gamboge acid, gambogic acid, gambogoic acid
| Name | Gambogic acid | ||
| PubChem CID | 9852185 | ||
| Molecular Weight | 628.7g/mol | ||
| Synonyms |
gamboge acid, gambogic acid, gambogoic acid |
||
| Formula | C₃₈H₄₄O₈ | ||
| SMILES | CC(=CCCC1(C=CC2=C(C3=C(C(=C2O1)CC=C(C)C)OC45C6CC(C=C4C3=O)C(=O)C5(OC6(C)C)CC=C(C)C(=O)O)O)C)C | ||
| InChI | 1S/C38H44O8/c1-20(2)10-9-15-36(8)16-14-24-29(39)28-30(40)26-18-23-19-27-35(6,7)46-37(33(23)41,17-13-22(5)34(42)43)38(26,27)45-32(28)25(31(24)44-36)12-11-21(3)4/h10-11,13-14,16,18,23,27,39H,9,12,15,17,19H2,1-8H3,(H,42,43)/b22-13-/t23-,27+,36-,37+,38-/m1/s1 | ||
| InChIKey | GEZHEQNLKAOMCA-RRZNCOCZSA-N | ||
| CAS Number | 2752-65-0 | ||
| ChEMBL ID | CHEMBL555017 | ||
| Toxicity | Organism | Test Type | Route(Dose) |
| rat | LD50 | intraperitoneal(165 mg/kg) | |
| mouse | LD50 | intraperitoneal(254 mg/kg) | |
| rat | LD50 | oral(322 mg/kg) | |
| Structure | 
|
Download
2D
MOL
3D
MOL
|
|
| Chineses Pinyin | GouTeng | ||
| Use Part | Hooked Stem-Branch | ||
| Habitat | GuangXi, JiangXi, HuNan, SiChuan | ||
| Flavor | Sweet | ||
| Meridian Tropism | Liver, Pericardium | ||
| Chineses Pinyin | TengHuang | ||
| Use Part | Balsam | ||
| Habitat | India , Thailand , India | ||
| Flavor | Sour, Astringent | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Malpighiales
-->Family: Clusiaceae
-->Genus: Garcinia
-->Species: Garcinia hanburyi
|
||
| Chineses Pinyin | ErChaGouTeng | ||
| Use Part | Dry Decocted Paste Of Branch-Leaf | ||
| Habitat | ZheJiang, FuJian, GuangDong, GuangXi, JiangXi, HuNan, SiChuan, GuiZhou | ||
| Flavor | Sweet | ||
| Meridian Tropism | Liver, Pericardium | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Gentianales
-->Family: Rubiaceae
-->Genus: Uncaria
-->Species: Uncaria gambir
|
||
| Pair Name | Gambogic acid, NaI*131 | |||
| Partner Name | NaI*131 | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Expression | ABCB1 | hsa5243 |
| Up-regulation | Expression | BAX | hsa581 | |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Down-regulation | Expression | TP53 | hsa7157 | |
| In Vitro Model | A549/DDP | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_C0W4 |
| Result | The two drugs appear to have a synergistic effect on apoptosis of A549/DDP cells. | |||
| Pair Name | Gambogic acid, Cisplatin | |||
| Partner Name | Cisplatin | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G0/G1 phase | |||
| Gene Regulation | Down-regulation | Expression | ABCC2 | hsa1244 |
| Up-regulation | Expression | BAX | hsa581 | |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Down-regulation | Expression | LRP1 | hsa4035 | |
| In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
| Result | Combination of GA with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression. | |||
| Pair Name | Gambogic acid, Cisplatin | |||
| Partner Name | Cisplatin | |||
| Disease Info | [ICD-11: 2B51] | Osteosarcoma | Investigative | |
| Biological Phenomena | Induction-->Mitochondria-mediated apoptosis | |||
| Gene Regulation | Up-regulation | Expression | CASP8 | hsa841 |
| Up-regulation | Expression | CASP9 | hsa842 | |
| In Vitro Model | MG-63 | Osteosarcoma | Homo sapiens (Human) | CVCL_0426 |
| HOS | Osteosarcoma | Homo sapiens (Human) | CVCL_0312 | |
| U2OS | Osteosarcoma | Homo sapiens (Human) | CVCL_0042 | |
| Result | GA could increase the chemotherapeutic effect of CDDP in human osteosarcoma treatment through inducing the cell cycle arrest and promoting cell apoptosis | |||
| Pair Name | Gambogic acid, Cisplatin | |||
| Partner Name | Cisplatin | |||
| Disease Info | [ICD-11: 2B51] | Osteosarcoma | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Expression | CASP3 | hsa836 |
| Up-regulation | Cleavage | CASP8 | hsa841 | |
| Up-regulation | Expression | FAS | hsa355 | |
| Up-regulation | Expression | MAPK14 | hsa1432 | |
| In Vitro Model | MG-63 | Osteosarcoma | Homo sapiens (Human) | CVCL_0426 |
| HOS | Osteosarcoma | Homo sapiens (Human) | CVCL_0312 | |
| In Vivo Model | 0.2 mL of MG63 cell suspension (1.5×10⁷ cells/ml) was subcutaneously injected into the right flank of mice | |||
| Result | Our results demonstrate that GA may be a new potent therapeutic agent useful for targeting human OS cells. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Role of gambogic acid and NaI131 in A549/DDP cells. Oncol Lett. 2017 Jan;13(1):37-44. doi: 10.3892/ol.2016.5435. | Click |
| 2 | Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression. Onco Targets Ther. 2016 Jun 2;9:3359-68. doi: 10.2147/OTT.S100936. | Click |
| 3 | Viability inhibition effect of gambogic acid combined with cisplatin on osteosarcoma cells via mitochondria-independent apoptotic pathway. Mol Cell Biochem. 2013 Oct;382(1-2):243-52. doi: 10.1007/s11010-013-1740-5. | Click |
| 4 | Hypoxia-induced resistance to cisplatin-mediated apoptosis in osteosarcoma cells is reversed by gambogic acid independently of HIF-1α. Mol Cell Biochem. 2016 Sep;420(1-2):1-8. doi: 10.1007/s11010-016-2759-1. | Click |
